



UNITED STATES PATENT AND TRADEMARK OFFICE

OCT - 1 2010

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Philip S. Johnson, Esq.
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08816

In Re: Patent Term Extension
Application for
U.S. Patent No. 5,254,556

Dear Mr. Johnson :

An order granting interim extension under 35 U.S.C. § 156(e)(2) is enclosed extending the term of U.S. Patent No. 5,254,556 for a period of one year from the previously extended expiration date. While a courtesy copy of this letter is being forwarded to the Food and Drug Administration (FDA), you should directly correspond with the FDA regarding any required changes to the patent expiration dates set forth in the Patent and Exclusivity Data Appendix of the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations). As of August 18, 2003, patent information is required to be submitted on FDA Form 3542 depending on the approval status of the application. Form FDA 3542 is the only form that will be used for Orange Book publication the forms can be found at:
<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM048345.pdf>

Inquiries regarding this communication should be directed to the undersigned by telephone at (571) 272-7755, or by e-mail at mary.till@uspto.gov.



Mary C. Till
Legal Advisor
Office of Patent Legal Administration
Office of the Associate Commissioner
for Patent Examination Policy

cc: Office of Regulatory Policy
 Food and Drug Administration
 10903 New Hampshire Ave., Bldg. 51, Rm. 6222
 Silver Spring, MD 20993-0002

RE: Invega Sustenna®
FDA Docket No.:

Attention: Beverly Friedman

UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Ortho-McNeil-Janssen Pharmaceuticals, Inc. :
Request for Patent Term Extension : ORDER GRANTING
U.S. Patent No. 5,254,556 : INTERIM EXTENSION


Ortho-McNeil-Janssen Pharmaceuticals, Inc., the owner of record in the United States Patent and Trademark Office (USPTO) of U.S. Patent No. 5,254,556, filed an application for patent term extension under 35 U.S.C. § 156 on August 6, 2009. The original term of the patent expired on October 27, 2009. The patent claims paliperidone palmitate, labeled as the active ingredient in the human drug product Invega Sustenna®, which was approved by the Food and Drug Administration for commercial marketing or use on July 31, 2009. An extension of 1,449 days is requested.

The initial USPTO review of the application to date indicates that the subject patent is eligible for extension under 35 U.S.C. § 156. Because the extended term of the patent would expire before a certificate of patent term extension can be issued, an additional interim extension of the patent term is appropriate.

A second interim extension under 35 U.S.C. § 156(e)(2) of the term of U.S. Patent No. 5,254,556 is granted for a period of one year from the extended expiration date of the patent, i.e., until October 27, 2011.

October 1, 2010

Date



David J. Kappos

Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office